Digest Network Come funziona
Network
/
Società
Jo
Non verificato

Johnson & Johnson

Di cosa scriviamo

BiotecnologiaFarmaceuticaSaluteSanitàWeb e Social Network

95 comunicati stampa

Guarda tutti i comunicati
22/07/2026
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
16/07/2026
Sanità
Farmaceutica
Fitness
Libri/Editoria
Medicina - Varie
Biotecnologia
Assistenza all'Infanzia
Comunicazione
Management
Salute
Medicina sportiva
Eventi
Appalti e gare
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
15/07/2026
Biotecnologia
Farmaceutica
Salute
Titoli e azioni
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
15/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
08/07/2026
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
25/06/2026
Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
15/06/2026
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
11/06/2026
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
08/06/2026
Mercato azionario
Oncologia
Attrezzature medico-sanitarie
Salute
Sanità
Farmaceutica
Biotecnologia
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Fonte
Johnson & Johnson
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0